Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.005 | 0.0846 | 0.7319 |
Schistosoma mansoni | tar DNA-binding protein | 0.0064 | 0.1157 | 1 |
Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0016 | 0.0064 | 0.0064 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0013 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0013 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0016 | 0.0064 | 0.0549 |
Schistosoma mansoni | tar DNA-binding protein | 0.0064 | 0.1157 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0034 | 0.0484 | 0.4186 |
Trypanosoma brucei | cAMP-specific phosphodiesterase | 0.0013 | 0 | 0.5 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0016 | 0.0064 | 0.0549 |
Schistosoma mansoni | tar DNA-binding protein | 0.0064 | 0.1157 | 1 |
Leishmania major | cAMP phosphodiesterase A, putative;with=GeneDB:LinJ18_V3.1100 | 0.0013 | 0 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0064 | 0.1157 | 0.1157 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0013 | 0 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0064 | 0.1157 | 0.1157 |
Leishmania major | cAMP-specific phosphodiesterase, putative | 0.0013 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0013 | 0 | 0.5 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0016 | 0.0064 | 0.0549 |
Loa Loa (eye worm) | RNA binding protein | 0.0064 | 0.1157 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0064 | 0.1157 | 1 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.005 | 0.0846 | 0.7319 |
Trypanosoma cruzi | cAMP phosphodiesterase A, putative | 0.0013 | 0 | 0.5 |
Trypanosoma brucei | cAMP-specific phosphodiesterase, putative | 0.0013 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0016 | 0.0064 | 0.0549 |
Loa Loa (eye worm) | hypothetical protein | 0.0016 | 0.0064 | 0.0549 |
Echinococcus multilocularis | high affinity cAMP specific 3',5' cyclic | 0.0454 | 1 | 1 |
Trypanosoma cruzi | cAMP specific phosphodiesterase, putative | 0.0013 | 0 | 0.5 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0194 | 0.4102 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0016 | 0.0064 | 0.0549 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0013 | 0 | 0.5 |
Trypanosoma cruzi | cyclic nucleotide phosphodiesterase | 0.0013 | 0 | 0.5 |
Trypanosoma cruzi | cAMP phosphodiesterase A, putative | 0.0013 | 0 | 0.5 |
Trypanosoma cruzi | cAMP specific phosphodiesterase, putative | 0.0013 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0064 | 0.1157 | 1 |
Trypanosoma brucei | 3', 5'-cyclic nucleotide phosphodiesterase, putative | 0.0013 | 0 | 0.5 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0194 | 0.4102 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.005 | 0.0846 | 0.7319 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0064 | 0.1157 | 1 |
Trypanosoma brucei | cAMP phosphodiesterase A, putative | 0.0013 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0013 | 0 | 0.5 |
Trypanosoma brucei | cAMP-specific phosphodiesterase | 0.0013 | 0 | 0.5 |
Giardia lamblia | CAMP-specific 3,5-cyclic phosphodiesterase 4B | 0.0013 | 0 | 0.5 |
Echinococcus multilocularis | GPCR, family 2 | 0.0016 | 0.0064 | 0.0064 |
Leishmania major | hypothetical protein, conserved | 0.0013 | 0 | 0.5 |
Echinococcus granulosus | GPCR family 2 | 0.0016 | 0.0064 | 0.0064 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0064 | 0.1157 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0064 | 0.1157 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0034 | 0.0484 | 0.4186 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0194 | 0.4102 | 1 |
Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0016 | 0.0064 | 0.0064 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0013 | 0 | 0.5 |
Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0016 | 0.0064 | 0.0064 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0194 | 0.4102 | 0.5 |
Trypanosoma cruzi | cAMP specific phosphodiesterase, putative | 0.0013 | 0 | 0.5 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0016 | 0.0064 | 0.0549 |
Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0016 | 0.0064 | 0.0064 |
Loa Loa (eye worm) | hypothetical protein | 0.005 | 0.0846 | 0.7319 |
Chlamydia trachomatis | enoyl-acyl-carrier protein reductase | 0.0194 | 0.4102 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0016 | 0.0064 | 0.0549 |
Trypanosoma cruzi | cAMP-specific phosphodiesterase, putative | 0.0013 | 0 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0013 | 0 | 0.5 |
Giardia lamblia | hypothetical protein | 0.0013 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0194 | 0.4102 | 0.5 |
Trypanosoma cruzi | cAMP specific phosphodiesterase, putative | 0.0013 | 0 | 0.5 |
Trichomonas vaginalis | hypothetical protein | 0.0194 | 0.4102 | 1 |
Trypanosoma brucei | 3', 5'-cyclic nucleotide phosphodiesterase, putative | 0.0013 | 0 | 0.5 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0194 | 0.4102 | 0.5 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0034 | 0.0484 | 0.4186 |
Brugia malayi | RNA binding protein | 0.0064 | 0.1157 | 1 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0194 | 0.4102 | 1 |
Brugia malayi | TAR-binding protein | 0.0064 | 0.1157 | 1 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0013 | 0 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.